Nifekalant

Nifekalant is a fast-acting Class III antiarrhythmic intravenous medication mainly approved in Japan (under the brand name Shinbit) to treat life-threatening heart rhythm disorders, including sustained ventricular tachycardia and ventricular fibrillation. It works as a selective potassium channel blocker to stabilize electrical activity in the heart. Its therapeutic use is listed as antiarrhythmics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include nifekalantum and nifekalant. Its PubChem CID is 4486.

CAS No 130636-43-0
Molecular Formula C19H27N5O5
Molecular Weight 405.40 g/mol
Synonyms 6-[2-[2-hydroxyethyl-[3-(4-nitrophenyl)propyl]amino]ethylamino]-1,3-dimethylpyrimidine-2,4-dione

Frequently Asked Questions